Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-04-29 | Dr. Harris has a Ph.D. and D.Sc. in scientific fields and has held senior executive positions but no direct mention of software or programming skills. |
| 2017-04-26 | Dr. Harris is a molecular biologist and biochemist with executive roles in pharmaceutical companies and venture capital, with degrees in virology and biochemistry, but no software or programming background noted. |
| 2017-12-18 | Timothy J.R. Harris, Ph.D., D.Sc.: Consists of (i) 57,7116 shares of common stock, (ii) currently exercisable warrants to acquire an additional 39,187 shares of common stock, (iii) stock options to purchase 51,409 shares of common stock that are currently vested or that will become vested within 60 days, and (iv) 39,292 restricted stock units. |
| 2018-04-30 | Dr. Harris is a molecular biologist, biochemist and geneticist by training and is currently EVP R&D at Bioverativ Inc, a Sanofi Company. He was the Chief Technology Officer and Director of the Advanced Technology Program at SAIC-Frederick, Inc. in Maryland from January 2007 to June 2011, which operates the National Cancer Institute’s leading center for cancer and AIDS research. |
Data sourced from SEC filings. Last updated: 2026-03-05